← FDA DRUG APPROVALS
FDA ANDA · ANDA214053
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor: APOTEX
APPLICATION
ANDA214053
TYPE
ANDA
ORIGINAL APPROVAL
2024-05-17
LATEST ACTION
2024-05-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATEDiscontinued
EMTRICITABINE 200MG, TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET · ORAL
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATEDiscontinued
EMTRICITABINE 120MG, TENOFOVIR ALAFENAMIDE FUMARATE EQ 15MG BASE · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.